Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages 117-123

  Rallón, Norma I ^a   Pineda, Juan A ^b   Soriano, Vincent ^a   Neukam, Karin ^b   Vispo, Eugenia ^a   Rivero, Antonio ^c   Labarga, Pablo ^a   Caruz, Antonio ^d   Restrepo, Clara ^a   Camacho, Angela ^c   Barreiro, Pablo ^a   Benito, Jose M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

HCV subtypes; HIV HCV coinfection; IFN lambda; IL28B; Viral kinetics

Indexed keywords

CYSTEINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPLETE EARLY VIROLOGICAL RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; EARLY VIROLOGICAL RESPONSE; END OF TREATMENT VIROLOGICAL RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 3; HEPATITIS C VIRUS SUBTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; SUSTAINED VIROLOGICAL RESPONSE; VIRUS GENE; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84862117053     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824f5506     Document Type: Article

References (29)

1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med. 2001;345: 41-52. (Pubitemid 32634271)
2. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089. (Pubitemid 46763278)
3. Ghany M, Strader D, Thomas D, et al. and American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
4. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634-651.
5. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
6. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
7. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
8. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24: F23-F29.
9. Thompson A, Muir A, Sulkowsky M, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.
10. Stättermayer A, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344-350.
11. Rallon NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin. AIDS. 2011;25:1025-1033.
12. Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313-320.
13. Hofmann W, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8:257-264.
14. Poordard F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
15. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
16. Sarrazin C, Zeuzem S. Resistance to direct acting antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138: 447-462.
17. Naggie S, Patel K, MucHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother. 2010;65:2063-2069.
18. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51: 788-795.
19. Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis. 2009; 49:1397-1401.
20. Chevaliez S, Bouvier-Alias M, Brillet R, et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009;4:e8209.
21. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128: 343-350. (Pubitemid 40439195)
22. Kirk G, Astemborski J, Mehta S, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48: 963-972.
23. Ferreira P, Santos C, Cortes R, et al. Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil. J Antimicrob Chemother. 2012;67: 509-510.
24. Natterman J, Vogel M, Nischalke H, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis. 2011;203: 595-601.
25. Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One. 2010; 5:e13771.
26. de Araujo E, Dahari H, Cotler S, et al. Pharmacodynamics of PEGIFN- α2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2011;56: 95-99.
27. Rivero-Juarez A, Camacho A, Perez-Camacho I, et al. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother. 2012;67:202-205.
28. Jensen D, Morgan T, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40Kd)/ribavirin therapy. Hepatology. 2006;43:954-960. (Pubitemid 43724620)
29. McPhee F, Hernandez D, Yu F, et al. Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. J Hepatol. 2011;54(suppl 1):28-29.